Sangeetha Venugopal, MD, MS

home / authors / sangeetha-venugopal-md-ms

Sangeetha Venugopal, MD, MS, is a physician in the Department of Medicine, Division of Hematology, at the Sylvester Comprehensive Cancer Center at the University of Miami.

Articles

Using MRD to Predict Outcomes in Acute Myeloid Leukemia

Using MRD to Predict Outcomes in Acute Myeloid Leukemia

Sangeetha Venugopal, MD, MS
September 4th 2024

Sangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.

Navigating the Molecular Landscape of Acute Myeloid Leukemia

Navigating the Molecular Landscape of Acute Myeloid Leukemia

Sangeetha Venugopal, MD, MS
September 3rd 2024

Sangeetha Venugopal, MD, MS, discusses the dynamic landscape of molecular targets in acute myeloid leukemia.

Venugopal on the Unmet Needs in AML Treatment

Venugopal on the Unmet Needs in AML Treatment

Sangeetha Venugopal, MD, MS
August 24th 2024

Sangeetha Venugopal, MD, MS, discusses what she is most interested about regarding unmet needs in patients with AML.

Advancements in AML Treatment in the Past 10 Years

Advancements in AML Treatment in the Past 10 Years

Sangeetha Venugopal, MD, MS
August 23rd 2024

Sangeetha Venugopal, MD, MS, discusses the evolving field of acute myeloid leukemia treatment.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: September 18th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non–Small Cell Lung Cancer
Published: September 15th 2024 | Updated: September 18th 2024
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non–Small Cell Lung Cancer
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
Published: July 17th 2024 | Updated: September 18th 2024
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL
Published: June 2nd 2023 | Updated: September 18th 2024
ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL
Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma
Published: September 15th 2024 | Updated: September 18th 2024
Atezolizumab After Vemurafenib and Cobimetinib Shows Trend Toward Better OS in Melanoma